Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 43817-133

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 43817-133). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Panacea Biotec Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 01

A line graph depicting the estimated probability of response over time (up to 2 hours post-dose) for placebo and rizatriptan benzoate tablets at 5 mg and 10 mg doses. The graph shows response rates increasing with time and higher probabilities for the 10 mg dose compared to 5 mg and placebo.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 02

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, rizatriptan benzoate tablets 5 mg, and rizatriptan benzoate tablets 10 mg. The x-axis represents hours post-dose, and the y-axis shows probability percentages ranging from 0% to 100%. The graph illustrates increasing probabilities for all groups over time, with placebo showing the highest curve, followed by 5 mg and 10 mg tablet doses.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 03

Line graph showing the estimated probability of response over time (up to 2 hours post-dose) comparing Placebo, Rizatriptan Benzoate Orally Disintegrating Tablets 5 mg, and 10 mg doses. The graph illustrates increasing response probabilities with higher doses and time post-dose.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 04

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo and two doses of Rizatriptan Benzoate Orally Disintegrating Tablets (5 mg and 10 mg). The Y-axis represents the probability percentage, and the X-axis represents hours post-dose. The graph compares active doses to placebo.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 05

A line graph comparing the effects of Rizatriptan Benzoate Orally Disintegrating Tablets versus placebo over time. The x-axis represents hours post Stage 2 dose (0.5 to 2.0 hours), and the y-axis shows percentage response with 95% confidence intervals. The graph displays increasing response percentages for the tablet group compared to placebo across the time points.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 06

Label for Rizatriptan Benzoate orally disintegrating tablets, USP 5 mg strength, manufactured by Panacea Biotec Pharma Ltd. and distributed by Bionpharma Inc., USA. The label includes dosage information, NDC 43817-133-03, and features barcodes and peel tabs for individual tablets. The text specifies that each tablet contains 7.265 mg of rizatriptan benzoate, USP equivalent to 5 mg of rizatriptan base.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 07

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg by Panacea Biotec Limited. The label indicates tablets in unit-dose packaging with 18 units per carton (6 blisters of 3 tablets each). Label includes dosing strength, manufacturer details, bar code, and instructions for alternatively opening the unit-dose pack.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 08

Packaging label for Rizatriptan Benzoate orally disintegrating tablets, USP, 10 mg strength. The label includes the drug name, strength in highlighted orange, NDC 43817-135-03, and dosage form. It states each tablet contains 14.53 mg of rizatriptan benzoate equivalent to 10 mg rizatriptan base. Manufactured by Panacea Biotec Pharma Ltd., India, and distributed by Bionpharma Inc., USA. The label also includes a barcode and peel-off sections for individual tablets.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 09

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 10 mg by Panacea Biotec Limited. The label shows 18 unit-dose tablets packaged as 6 blisters of 3 unit-doses each. It includes manufacturer and distributor information, usage instructions for removing tablets from the blister pack, and a barcode.*

FDA Label Image

2ace0595 6732 4295 A786 Cad3e909a95e 88 1

Chemical structure of rizatriptan benzoate, showing the molecular arrangement of rings and functional groups characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.